Accretion Nutrav

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE1KVQ01019
  • NSEID:
  • BSEID: 544694
INR
268.00
8 (3.08%)
BSENSE

Jun 23, 03:30 PM

BSE+NSE Vol: 30000

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

30.0 k (294.74%) Volume

Shareholding (Mar 2026)

FII

1.08%

Held by 1 FIIs

DII

7.00%

Held by 0 DIIs

Promoter

73.48%

Why is Accretion Nutraveda Ltd falling/rising?

23-Jun-2026

As of 22-Jun, Accretion Nutraveda Ltd's stock price is currently at 260.00, reflecting a 1.92% increase despite recent declines over the past week and month. The stock's price is above its moving averages, indicating a positive trend, and it has outperformed its sector today.

As of 22-Jun, Accretion Nutraveda Ltd's stock price is rising, currently at 260.00, reflecting a change of 4.9 or 1.92% increase. This upward movement is notable despite the stock's performance over the past week and month, where it has shown declines of 3.17% and 1.14%, respectively. However, today's performance indicates that the stock has outperformed its sector by 0.92%. <BR><BR>Additionally, the stock's current price is higher than its 50-day, 100-day, and 200-day moving averages, suggesting a positive trend in the short to medium term. Although the stock has experienced erratic trading, not trading on 3 out of the last 20 days, it remains liquid enough for trading activities. Overall, the combination of today's positive performance and the stock's position relative to its moving averages contributes to the observed rise in its price.

View full answer

Which are the latest news on Accretion Nutrav?

23-Jun-2026

What does Accretion Nutrav do?

11-Jun-2026

Accretion Nutraveda Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, incorporated in 2021 and converted to a Public Limited Company in 2025. It currently has no available revenue or profit data, with a market cap of INR 188 Cr and a P/E ratio of 37.00.

Overview:<BR>Accretion Nutraveda Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Accretion Nutraveda Ltd was incorporated as a Private Limited Company on March 16, 2021, and later converted to a Public Limited Company on May 2, 2025. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 188 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 37.00<BR>Industry P/E: 34<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.00<BR>Return on Equity: 0.00%<BR>Price to Book: 0.00<BR><BR>Contact Details:<BR>Registrar Address: Not available.

View full answer

How big is Accretion Nutrav?

11-Jun-2026

As of 10th June, Accretion Nutraveda Ltd has a market capitalization of 188.00 Cr, categorized as a Micro Cap. There is no valid financial data available for net sales, net profit, or balance sheet metrics for the latest periods.

As of 10th June, <BR><BR>Market Cap: Accretion Nutraveda Ltd has a market capitalization of 188.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: There is no valid balance sheet data available for the latest annual period, including values for Shareholder's Funds and Total Assets.

View full answer

Who are the peers of the Accretion Nutrav?

11-Jun-2026

Accretion Nutrav's peers include Kerala Ayurveda, Nectar Lifesci., Syschem (India), Brooks Lab., Oxygenta Pharma, Coral Labs., Sanjiv.Parant., and Natural Capsules. Management risks vary, with good ratings for Sanjiv.Parant. and Syschem (India), while 1-year returns range from -64.41% for Kerala Ayurveda to 427.17% for Guj. Inject(Ker).

Peers: The peers of Accretion Nutrav are Kerala Ayurveda, Nectar Lifesci., Syschem (India), Brooks Lab., Oxygenta Pharma, Coral Labs., Sanjiv.Parant., Natural Capsules.<BR><BR>Quality Snapshot: Below Average management risk is observed at Kerala Ayurveda, Syschem (India), Brooks Lab., Coral Labs., and Natural Capsules, while Average management risk is found at Nectar Lifesci. Good management risk is noted at Sanjiv.Parant. For growth, Good growth is seen at Syschem (India) and Sanjiv.Parant., while Below Average growth is present at Kerala Ayurveda, Nectar Lifesci., Brooks Lab., Oxygenta Pharma, Coral Labs., and Natural Capsules. In terms of Capital Structure, Excellent capital structure is noted at Coral Labs., while Good capital structure is found at Syschem (India) and Sanjiv.Parant., with Below Average capital structure at the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Guj. Inject(Ker) at 427.17%, while the peer with the lowest 1-year return is Kerala Ayurveda at -64.41%. Accretion Nutrav's 1-year return is not available for comparison. Additionally, several peers, including Oxygenta Pharma, Sanjiv.Parant., and Natural Capsules, have negative six-month returns.

View full answer

When is the next results date for Accretion Nutraveda Ltd?

05-May-2026

The next results date for Accretion Nutraveda Ltd is 08 May 2026.

The next results date for Accretion Nutraveda Ltd is scheduled for 08 May 2026.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 188 Cr (Micro Cap)

stock-summary
P/E

38.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
37.44%
0%
37.44%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Accretion Nutrav for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

Announcements stock-summary

Announcement under Regulation 30 (LODR)-Press Release / Media Release

15-May-2026 | Source : BSE

Accretion Nutraveda Limited has informed the Exchange regarding Press Release dated 15th May 2026 titled Company Delivers Robust Performance in H2 FY26 : Revenue up 80.09% YOY and EBITDA up 42.64% and growth Driven by strong demand Operational Expansion and Expanding Market Presence.

Announcement under Regulation 30 (LODR)-Resignation of Director

08-May-2026 | Source : BSE

Please find enclosed herewith resignation of Mr. Mahipal singh chouhan as non-Executive Independent Director of the Company.

Appointment Of Internal Auditors

08-May-2026 | Source : BSE

Please find enclosed herewith Intimation with respect to Appointment Internal Auditor of the company.

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
3.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
18.36%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.08%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
38
Industry P/E
34
Price to Book Value
NA
EV to EBIT
29.27
EV to EBITDA
28.16
EV to Capital Employed
NA
EV to Sales
5.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
NA
ROE (Latest)
NA

Technicals key factors

Indicator
Weekly
Monthly
MACD
RSI
Bearish
Bollinger Bands
Bullish
KST
Dow Theory
Mildly Bullish
OBV
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 1 FIIs (1.08%)

Promoter with highest holding

Ankurkumar Shantilal Patel (14.7%)

Highest Public shareholder

Unicorn Fund (6.59%)

Individual Investors Holdings

14.19%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Accretion Nutrav"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Mar 2026 is 38.98% vs 29.59% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Mar 2026 is 15.45% vs 35.47% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.54",
          "val2": "14.06",
          "chgp": "38.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.56",
          "val2": "3.29",
          "chgp": "8.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.27",
          "val2": "0.26",
          "chgp": "3.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.69",
          "val2": "2.33",
          "chgp": "15.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "18.22%",
          "val2": "23.40%",
          "chgp": "-5.18%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Accretion Nutrav"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 110.00% vs 219.36% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 102.80% vs 204.88% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "33.60",
          "val2": "16.00",
          "chgp": "110.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "6.89",
          "val2": "3.72",
          "chgp": "85.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.53",
          "val2": "0.35",
          "chgp": "51.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "5.07",
          "val2": "2.50",
          "chgp": "102.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "20.51%",
          "val2": "23.25%",
          "chgp": "-2.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Half Yearly Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Sep'25
Change(%)
Net Sales
19.54
14.06
38.98%
Operating Profit (PBDIT) excl Other Income
3.56
3.29
8.21%
Interest
0.27
0.26
3.85%
Exceptional Items
0.00
0.00
Standalone Net Profit
2.69
2.33
15.45%
Operating Profit Margin (Excl OI)
18.22%
23.40%
-5.18%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Mar 2026 is 38.98% vs 29.59% in Sep 2025

Direction Arrows
Standalone Net Profit

Growth in half year ended Mar 2026 is 15.45% vs 35.47% in Sep 2025

Annual Results Snapshot (Standalone) - Mar'26stock-summary

Mar'26
Mar'25
Change(%)
Net Sales
33.60
16.00
110.00%
Operating Profit (PBDIT) excl Other Income
6.89
3.72
85.22%
Interest
0.53
0.35
51.43%
Exceptional Items
0.00
0.00
Standalone Net Profit
5.07
2.50
102.80%
Operating Profit Margin (Excl OI)
20.51%
23.25%
-2.74%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 110.00% vs 219.36% in Mar 2025

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2026 is 102.80% vs 204.88% in Mar 2025

stock-summaryCompany CV
About Accretion Nutraveda Ltd stock-summary
stock-summary
Accretion Nutraveda Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Accretion Nutraveda Limited was initially incorporated as a Private Limited Company on March 16, 2021 and has subsequently, converted the status into a Public Limited Company vide Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre w.e.f. May 2, 2025.
Company Coordinates stock-summary
Icon
No Company Details Available